Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemotherapy plus surgery versus surgery alone for operable non-small cell lung cancer
NL-OMON27849Active, not recruiting
- Sponsor
- MRC Clinical Trials Unit at UCL
- Start
- Jul 2001
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of gemcitabine, cisplatin, docetaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by MRC Clinical Trials Unit at UCL. Primary endpoint: 3-year survival rate. Started Jul 2001; status: active, not recruiting.
02
Drugs
gemcitabinecisplatindocetaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON27849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27849.